[HTML][HTML] QGC606: A best-in-class orally active centrally acting aminopeptidase A inhibitor prodrug for treating heart failure following myocardial infarction
SE Boitard, M Keck, R Deloux, PE Girault-Sotias… - Canadian Journal of …, 2022 - Elsevier
Background Blockade of brain renin-angiotensin system (RAS) overactivity by firibastat, the
first centrally acting aminopeptidase A (APA) inhibitor prodrug, has already demonstrated its
effectiveness in improving cardiac function after myocardial infarction (MI). We developed
QGC606, a more potent and more selective APA inhibitor prodrug and studied its effects
after long-term oral administration in mice post-MI. Methods Two days after MI induced by
the left anterior descending artery ligation, adult male mice were randomized into 4 groups …
first centrally acting aminopeptidase A (APA) inhibitor prodrug, has already demonstrated its
effectiveness in improving cardiac function after myocardial infarction (MI). We developed
QGC606, a more potent and more selective APA inhibitor prodrug and studied its effects
after long-term oral administration in mice post-MI. Methods Two days after MI induced by
the left anterior descending artery ligation, adult male mice were randomized into 4 groups …
以上显示的是最相近的搜索结果。 查看全部搜索结果